J&J ditch­es epilep­sy de­vel­op­ment with Ad­dex, blind­sid­ing 20-year part­ner

John­son & John­son has dis­con­tin­ued in­vest­ment in an epilep­sy pro­gram out of 20-year part­ner Ad­dex Ther­a­peu­tics a few months af­ter the Gene­va-based biotech’s drug flunked …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER